In This Article:
3SBio and Health and Happiness (H&H) International Holdings can add profound upside to your portfolio. This is because the optimistic growth outlook for their profitability and returns make their high-growth potential appealing relative to their peers. Below I’ve put together a list of great potential investments for you to consider adding to your portfolio if growth is a dimension you would like to firm up.
3SBio Inc. (SEHK:1530)
3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. Formed in 2006, and currently run by Jing Lou, the company employs 4,051 people and with the company’s market capitalisation at HKD HK$51.28B, we can put it in the large-cap category.
1530’s forecasted bottom line growth is an optimistic 22.44%, driven by the underlying 69.01% sales growth over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 19.29%. 1530’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Want to know more about 1530? Other fundamental factors you should also consider can be found here.
Health and Happiness (H&H) International Holdings Limited (SEHK:1112)
Health and Happiness (H&H) International Holdings Limited, an investment holding company, manufactures and sells family nutrition and baby care products in Mainland China, Australia, New Zealand, and internationally. Founded in 1999, and run by CEO Fei Luo, the company employs 2,495 people and with the market cap of HKD HK$36.82B, it falls under the large-cap category.
An outstanding 24.37% earnings growth is forecasted for 1112, driven by an underlying sales growth of 40.66% over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 25.81%. 1112’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Thinking of investing in 1112? Other fundamental factors you should also consider can be found here.